Literature DB >> 20133073

Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer.

Sabbir Hossain1, Ping Xia, Kim Huang, Martina Descovich, Cynthia Chuang, Alexander R Gottschalk, Mack Roach, Lijun Ma.   

Abstract

PURPOSE: The treatment planning quality between nonisocentric CyberKnife (CK) and isocentric intensity modulation treatment was studied for hypofractionated prostate body radiotherapy. In particular, the dose gradient across the target and the critical structures such as the rectum and bladder was characterized. METHODS AND MATERIALS: In the present study, patients treated with CK underwent repeat planning for nine fixed-field intensity-modulated radiotherapy (IMRT) using identical contour sets and dose-volume constraints. To calculate the dose falloff, the clinical target volume contours were expanded 30 mm anteriorly and posteriorly and 50 mm uniformly in other directions for all patients in the CK and IMRT plans.
RESULTS: We found that all the plans satisfied the dose-volume constraints, with the CK plans showing significantly better conformity than the IMRT plans at a relative greater dose inhomogeneity. The rectal and bladder volumes receiving a low dose were also lower for CK than for IMRT. The average conformity index, the ratio of the prescription isodose volume and clinical target volume, was 1.18 +/- 0.08 for the CK plans vs. 1.44 +/- 0.11 for the IMRT plans. The average homogeneity index, the ratio of the maximal dose and the prescribed dose to the clinical target volume, was 1.45 +/- 0.12 for the CK plans vs. 1.28 +/- 0.06 for the IMRT plans. The average percentage of dose falloff was 2.9% +/- 0.8%/mm for CK and 3.1% +/- 1.0%/mm for IMRT in the anterior direction, 3.8% +/- 1.6%/mm for CK and 3.2% +/- 1.9%/mm for IMRT in the posterior direction, and 3.6% +/- 0.4% for CK and 3.6% +/- 0.4% for IMRT in all directions.
CONCLUSION: Nonisocentric CK was as capable of producing equivalent fast dose falloff as high-number fixed-field IMRT delivery. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20133073     DOI: 10.1016/j.ijrobp.2009.07.1752

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Development of raster scanning IMRT using a robotic radiosurgery system.

Authors:  Hiroya Shiomi; Yuichi Akino; Iori Sumida; Norihisa Masai; Ryoong-Jin Oh; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2021-03-10       Impact factor: 2.724

2.  Correlation and prediction uncertainties in the cyberknife synchrony respiratory tracking system.

Authors:  Eric W Pepin; Huanmei Wu; Yuenian Zhang; Bryce Lord
Journal:  Med Phys       Date:  2011-07       Impact factor: 4.071

3.  [Conventional versus hypofractionated intensity-modulated radiotherapy for prostate cancer].

Authors:  R Pahl
Journal:  Strahlenther Onkol       Date:  2012-09       Impact factor: 3.621

4.  Stereotactic body radiotherapy for prostate cancer: treatment approaches and clinical outcomes.

Authors:  Raymond Miralbell
Journal:  J Radiosurg SBRT       Date:  2011

5.  Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.

Authors:  Filippo Alongi; Rosario Mazzola; Alba Fiorentino; Stefanie Corradini; Dario Aiello; Vanessa Figlia; Fabiana Gregucci; Riccardo Ballario; Stefano Cavalleri; Ruggero Ruggieri
Journal:  Strahlenther Onkol       Date:  2018-07-12       Impact factor: 3.621

6.  Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

Authors:  Debra E Freeman; Christopher R King
Journal:  Radiat Oncol       Date:  2011-01-10       Impact factor: 3.481

7.  Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer.

Authors:  Eric K Oermann; Simeng Suy; Heather N Hanscom; Joy S Kim; Sue Lei; Xia Yu; Guowei Zhang; Brook Ennis; Joyann P Rohan; Nathaniel Piel; Benjamin A Sherer; Devin Borum; Viola J Chen; Gerald P Batipps; Nicholas L Constantinople; Stephen W Dejter; Gaurav Bandi; John Pahira; Kevin G McGeagh; Lucile Adams-Campbell; Reena Jha; Nancy A Dawson; Brian T Collins; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  J Hematol Oncol       Date:  2011-03-27       Impact factor: 17.388

Review 8.  Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.

Authors:  Nam P Nguyen; Rick Davis; Satya R Bose; Suresh Dutta; Vincent Vinh-Hung; Alexander Chi; Juan Godinez; Anand Desai; William Woods; Gabor Altdorfer; Mark D'Andrea; Ulf Karlsson; Richard A Vo; Thomas Sroka
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

9.  Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.

Authors:  Andrew W Ju; Hongkun Wang; Eric K Oermann; Benjamin A Sherer; Sunghae Uhm; Viola J Chen; Arjun V Pendharkar; Heather N Hanscom; Joy S Kim; Siyuan Lei; Simeng Suy; John H Lynch; Anatoly Dritschilo; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-01-31       Impact factor: 3.481

10.  Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Authors:  Leonard N Chen; Simeng Suy; Sunghae Uhm; Eric K Oermann; Andrew W Ju; Viola Chen; Heather N Hanscom; Sarah Laing; Joy S Kim; Siyuan Lei; Gerald P Batipps; Keith Kowalczyk; Gaurav Bandi; John Pahira; Kevin G McGeagh; Brian T Collins; Pranay Krishnan; Nancy A Dawson; Kathryn L Taylor; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-03-13       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.